Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Ophthalmic disease

Age-related macular degeneration (AMD)

Fibromodulin (FMOD)

In vitro and mouse studies suggest inhibiting FMOD could help treat AMD and other angiogenesis-dependent diseases. Comparative microarray analysis showed that FMOD was more highly expressed in nonpigmented than pigmented melanocytes. In a coculture system, human dermal microvascular endothelial cells (HMVECs) migrated in conditioned media from nonpigmented cells but did not migrate in media from pigmented melanocytes. In cultured mouse choroidal melanocytes, a neutralizing FMOD antibody or Fmod-targeting siRNA decreased proliferation and HMVEC migration compared with no treatment. Next steps could include identifying therapeutic targets in the FMOD angiogenic pathway.

SciBX 7(3); doi:10.1038/scibx.2014.97
Published online Jan. 23, 2014

Patent and licensing status unavailable

Adini, I. et al. J. Clin. Invest.;
published online Dec. 20, 2013;
doi:10.1172/JCI69404
Contact: Irit Adini, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
e-mail:
irit.adini@childrens.harvard.edu